636 related articles for article (PubMed ID: 33836681)
21. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
22. Genomic alterations in signet ring and mucinous patterned colorectal carcinoma.
Kim H; Kim BH; Lee D; Shin E
Pathol Res Pract; 2019 Oct; 215(10):152566. PubMed ID: 31400926
[TBL] [Abstract][Full Text] [Related]
23. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
25. NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction.
Li W; Qiu T; Guo L; Ying J; Zhou A
Pathol Res Pract; 2019 Mar; 215(3):483-489. PubMed ID: 30611619
[TBL] [Abstract][Full Text] [Related]
26. Colorectal carcinomas with mucinous differentiation are associated with high frequent mutation of KRAS or BRAF mutations, irrespective of quantity of mucinous component.
Li X; Sun K; Liao X; Gao H; Zhu H; Xu R
BMC Cancer; 2020 May; 20(1):400. PubMed ID: 32384877
[TBL] [Abstract][Full Text] [Related]
27. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
[TBL] [Abstract][Full Text] [Related]
28. Molecular spectrum of
Al-Shamsi HO; Jones J; Fahmawi Y; Dahbour I; Tabash A; Abdel-Wahab R; Abousamra AO; Shaw KR; Xiao L; Hassan MM; Kipp BR; Kopetz S; Soliman AS; McWilliams RR; Wolff RA
J Gastrointest Oncol; 2016 Dec; 7(6):882-902. PubMed ID: 28078112
[TBL] [Abstract][Full Text] [Related]
29. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
[TBL] [Abstract][Full Text] [Related]
30. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
31. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
32. ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer.
Fonseca AS; Ramão A; Bürger MC; de Souza JES; Zanette DL; de Molfetta GA; de Araújo LF; de Barros E Lima Bueno R; Aguiar GM; Plaça JR; Alves CP; Dos Santos ARD; Vidal DO; Silva GEB; Panepucci RA; Peria FM; Feres O; da Rocha JJR; Zago MA; Silva WA
BMC Cancer; 2021 Mar; 21(1):207. PubMed ID: 33648461
[TBL] [Abstract][Full Text] [Related]
33. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
34. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
35. Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights.
Dienstmann R; Elez E; Argiles G; Matos I; Sanz-Garcia E; Ortiz C; Macarulla T; Capdevila J; Alsina M; Sauri T; Verdaguer H; Vilaro M; Ruiz-Pace F; Viaplana C; Garcia A; Landolfi S; Palmer HG; Nuciforo P; Rodon J; Vivancos A; Tabernero J
Mol Oncol; 2017 Sep; 11(9):1263-1272. PubMed ID: 28618197
[TBL] [Abstract][Full Text] [Related]
36. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
[TBL] [Abstract][Full Text] [Related]
37. Histologic features and genomic alterations of primary colorectal adenocarcinoma predict growth patterns of liver metastasis.
Wu JB; Sarmiento AL; Fiset PO; Lazaris A; Metrakos P; Petrillo S; Gao ZH
World J Gastroenterol; 2019 Jul; 25(26):3408-3425. PubMed ID: 31341365
[TBL] [Abstract][Full Text] [Related]
38. Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.
El-Deiry WS; Vijayvergia N; Xiu J; Scicchitano A; Lim B; Yee NS; Harvey HA; Gatalica Z; Reddy S
Cancer Biol Ther; 2015; 16(12):1726-37. PubMed ID: 26553611
[TBL] [Abstract][Full Text] [Related]
39. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]